Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer

被引：0

作者：

Jia, Miaomiao ^{[1
]}

Yang, Haibo ^{[1
]}

Pan, Lihui ^{[1
]}

Gao, Jinnan ^{[1
]}

Guo, Fan ^{[1
]}

机构：

[1] Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Hosp 3,Shanxi Acad Med Sci,Dept Breast Surg, Taiyuan 030032, Peoples R China

来源：

BREAST JOURNAL | 2024年 / 2024卷

关键词：

breast cancer; estrogen receptor; human epidermal growth factor receptor 2; pathological complete response; OPEN-LABEL; RANDOMIZED MULTICENTER; TRASTUZUMAB; CHEMOTHERAPY; PERTUZUMAB; LAPATINIB; NEOSPHERE; EFFICACY; OUTCOMES; THERAPY;

D O I：

10.1155/2024/8851703

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: We aimed to investigate whether estrogen receptor (ER) status affects the predictive role of the human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) score on the efficacy of neoadjuvant treatment for HER2-positive breast cancer.Methods: This retrospective study comprised 167 individuals diagnosed with HER2-positive invasive breast cancer who had undergone neoadjuvant treatment and surgery. Uni- and multivariable logistic regression analyses were performed on the relationship between the HER2 IHC score and total pathological complete response (tpCR), breast pathological complete response (bpCR), or axillary partial response (apCR). Subgroup analyses were used to investigate whether the relationship between the HER2 IHC score and tpCR, bpCR, or apCR differed by ER or PR status.Results: The overall tpCR rate for HER2-positive breast cancers treated with neoadjuvant treatment was 41.32% (69 of 167). The tpCR, bpCR, and apCR rates were greater in the HER2 IHC 3+ group (tpCR: IHC 3 + 47.69% vs. IHC 2 + 18.92%, p=0.009). Significant interactions between HER2 IHC score and tpCR or bpCR were found in subgroup analyses based on ER status (tpCR: p for interaction = 0.001; bpCR: p for interaction = 0.001). Among ER-positive patients, the HER2 IHC 2+ group had substantially decreased tpCR, bpCR, and apCR rates than the HER2 IHC 3+ group (tpCR rate: p=0.003; bpCR rate: p=0.002; apCR rate: p=0.002). For ER-negative individuals, the tpCR, bpCR, and apCR rates did not differ significantly among the HER2 IHC 3+ versus HER2 IHC 2+ groups. Similarly, interactions between HER2 IHC score and tpCR, bpCR, or apCR were found in subgroup analyses based on PR status.Conclusion: HER2 IHC 2+ may indicate a decreased tpCR rate, bpCR rate, and apCR rate to neoadjuvant treatment in HR-positive patients having HER2-positive breast cancer, but not in HR-negative patients.

引用

页数：8

共 31 条

[1] Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer [J].

Alataki, Anastasia ;

Dowsett, Mitch .

[2] Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer [J].

Bi, Zhao ;

Chen, Peng ;

Liu, Yan-Bing ;

Zhao, Tong ;

Sun, Xiao ;

Song, Xian-Rang ;

Wang, Yong-Sheng .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) :397-405

[3] Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines [J].

Boero, Silvia ;

Morabito, Anna ;

Banelli, Barbara ;

Cardinali, Barbara ;

Dozin, Beatrice ;

Lunardi, Gianluigi ;

Piccioli, Patrizia ;

Lastraioli, Sonia ;

Carosio, Roberta ;

Salvi, Sandra ;

Levaggi, Alessia ;

Poggio, Francesca ;

D'Alonzo, Alessia ;

Romani, Massimo ;

Del Mastro, Lucia ;

Poggi, Alessandro ;

Pistillo, Maria Pia .

JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13

[4] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J].

Burstein, H. J. ;

Curigliano, G. ;

Thurlimann, B. ;

Weber, W. P. ;

Poortmans, P. ;

Regan, M. M. ;

Senn, H. J. ;

Winer, E. P. ;

Gnant, M. .

ANNALS OF ONCOLOGY, 2021, 32 (10) :1216-1235

[5] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 [J].

Burstein, H. J. ;

Curigliano, G. ;

Loibl, S. ;

Dubsky, P. ;

Gnant, M. ;

Poortmans, P. ;

Colleoni, M. ;

Denkert, C. ;

Piccart-Gebhart, M. ;

Regan, M. ;

Senn, H. -J. ;

Winer, E. P. ;

Thurlimann, B. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1541-1557

[6] Evolving standards of care and new challenges in the management of HER2-positive breast cancer [J].

Choong, Grace M. ;

Cullen, Grace D. ;

O'Sullivan, Ciara C. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (05) :355-374

[7] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[8] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (vol 28, pg 1700, 2017) [J].

Curigliano, G. ;

Burstein, H. J. ;

Winer, E. P. ;

Gnant, M. ;

Dubsky, P. ;

Loibl, S. ;

Colleoni, M. ;

Regan, M. M. ;

Piccart-Gebhart, M. ;

Senn, H. -J ;

Thurlimann, B. ;

Andre, F. ;

Baselga, J. ;

Bergh, J. ;

Bonnefoi, H. ;

Brucker, S. Y. ;

Cardoso, F. ;

Carey, L. ;

Ciruelos, E. ;

Cuzick, J. ;

Denkert, C. ;

Di Leo, A. ;

Ejlertsen, B. ;

Francis, P. ;

Galimberti, V. ;

Garber, J. ;

Gulluoglu, B. ;

Goodwin, P. ;

Harbeck, N. ;

Hayes, D. F. ;

Huang, C. -S. ;

Huober, J. ;

Khaled, H. ;

Jassem, J. ;

Jiang, Z. ;

Karlsson, P. ;

Morrow, M. ;

Orecchia, R. ;

Osborne, K. C. ;

Pagani, O. ;

Partridge, A. H. ;

Pritchard, K. ;

Ro, J. ;

Rutgers, E. J. T. ;

Sedlmayer, F. ;

Semiglazov, V. ;

Shao, Z. ;

Smith, I. ;

Toi, M. ;

Tutt, A. .

ANNALS OF ONCOLOGY, 2019, 30 (07) :1181-1181

[9] The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT) A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB) [J].

Fayanju, Oluwadamilola M. ;

Ren, Yi ;

Thomas, Samantha M. ;

Greenup, Rachel A. ;

Plichta, Jennifer K. ;

Rosenberger, Laura H. ;

Tamirisa, Nina ;

Force, Jeremy ;

Boughey, Judy C. ;

Hyslop, Terry ;

Hwang, Shelley .

ANNALS OF SURGERY, 2018, 268 (04) :591-601

[10] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia Valeria ;

Magazzu, Domenico ;

McNally, Virginia ;

Douthwaite, Hannah ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2016, 17 (06) :791-800

← 1 2 3 4 →